HEUKING advises Desitin Arzneimittel GmbH on sale of global rights to sulthiame
A HEUKING team led by Hamburg-based Partner Dr. Lothar Ende advised Desitin Arzneimittel GmbH on a significant life sciences transaction. Under the terms of the agreement, Desitin transferred the exclusive global rights to the patents covering sulthiame, an active ingredient used in the treatment of obstructive sleep apnea (OSA) and other sleep-related respiratory disorders, to U.S.-based biopharmaceutical company Apnimed, Inc.
Under the terms of the agreement, Desitin will receive an undisclosed upfront payment, future milestone payments, and royalties on future sales.
Sulthiame has already completed two successful Phase 2 clinical trials in Europe and features a novel mechanistic design that sets it apart from current therapeutic approaches. While the drug is already approved for other indications outside the U.S., plans are underway to explore its use for additional conditions such as Obesity Hypoventilation Syndrome (OHS).
HEUKING advised Desitin on all legal aspects of the transaction, with a particular focus on contract drafting and intellectual property structuring.
Counsel to Desitin Arzneimittel GmbH
HEUKING:
Dr. Lothar Ende (Lead), (M&A, Life Sciences), Hamburg,
Dr. Anton Horn,
Philipp Roman Schröler (both IP, Patents), both Düsseldorf
